Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Medical tourism continues to grow

Bart Van den Mooter, CEO of the TforG Group, looks at the drivers behind the rapid growth in Asia’s medical tourism market.

Asia Pacific is the fastest-growing region in the global medtech market. This growth is fuelled by public healthcare reforms, but even more so by the rapidly expanding private sector and with medical tourism, a connection not often made when the booming medtech market is talked about.

In most Association of Southeast Asian Nations countries, medical tourism represents a third or more of private hospital revenues. With every country looking to extract a piece of this pie, competition between countries and hospitals is intensifying.

In 2016, between 105 and 120 million medical tourists travelled abroad to seek healthcare services. This number is expected to grow by 10-14% annually in the coming three years. Worldwide medical tourism generated €150 billion (US$177 billion) in 2016 and is expected to grow to €200 billion by 2020.

The southeast Asian healthcare market is expanding faster than in other regions, especially driven by the private sector and, notably, medical tourism. Foreign patients are a major revenue generator for private hospitals in the region. Their share represents 40-55% of the private hospitals’ revenue in countries such as Singapore, Malaysia and especially Thailand. In India, medical tourism accounts for 25% of revenue, and in the Philippines, South Korea and Taiwan, it accounts for 10-15% of revenue.

In 2016, the medical tourism sector in Asia Pacific accounted for 10 million patients and €15-17 billion in revenues. For instance, India attracted more than 4 million medical tourists in 2016, generating around €4 billion in healthcare revenues. Similarly, in Thailand, which has perhaps the most advanced medical tourism sector, 3.5 million foreign patients spent more than €4 billion on healthcare in 2016. In Singapore, medical tourism accounted for almost €1.6 billion with close to 900,000 patients in 2016.

The sector will continue to grow 15-17% annually for the coming three years.

Due to fierce competition, private hospitals in the region regularly upgrade facilities and increase capacity. Recently, the sector has started attracting more international hospital groups and investors seeking to enter this lucrative market.

Countries seeking to develop medical tourism are teaming up with large multinational players – for example, Mayo Clinic with Raffles Medical Group in Singapore, Cleveland Clinic Abu Dhabi, John Hopkins Singapore and Anadolo Medical Centre in Turkey. While increasing competition between care providers is leading to differentiating investments and services, it is also leading to increased cost pressure and dilution in quality of healthcare.

The growth of medical tourism in southeast Asia obviously impacts the medtech market. Southeast Asia and India together represent more than €50 billion, or more than 10% of the global medtech market, and are growing faster (7.5%) than any other region in the world.

Market dynamics in the healthcare tourism segment impact the providers of medical equipment and devices in terms of product offerings and customer services. It also creates new opportunities for global as well as local medtech companies. With recent trends, there has been a shift to more day-care and ambulatory procedures in order to deal with staff shortages and cost-effectiveness.

There is also an increased need for telemedicine and e-health to improve the continuum of care. In recent times, medtech companies have increased group purchasing  and central warehousing and are also offering innovative IT-based and value-chain solutions to improve or defend their competitive advantage. They are also shifting from product-focused offerings to customised value-based solutions.

Both push factors and pull factors explain why the medical tourism market has taken off in the region and continues to grow.

Wealthy patients in emerging countries seek high-quality care in high-standard settings, which medical tourism destinations can offer. Middle class and underinsured patients in developed countries feel disenfranchised by their national healthcare systems, which are often plagued by long waiting times for treatments. They shop outside the organised medical system to find services that are affordable, timely or simply available.

Healthcare insurers motivate patients to seek more cost-effective medical provisions outside their home countries, and the usually lower cost of medical treatment in medical tourism destinations is an obvious attraction.

Moreover, national health insurance in developed countries does not typically cover some types of care, such as cosmetic surgery and dental care.

On the other hand, triggered by the opportunities of medical tourism, governments actively promote their countries and hospitals for patients shopping for healthcare services. Healthcare providers deploy referral systems to attract patients, and service companies offer innovative products to guide patients in their choice of country and hospital. To meet this demand, entrepreneurs are building technologically advanced facilities using foreign and domestic capital. They are hiring physicians, technicians and nurses trained to international standards, and where qualified personnel are not available locally, they are recruiting expatriates. Additionally, new service providers in these markets are also offering state-of-the-art healthcare technology for patients.

The increasing affordability of international air fares for intercontinental travel has also played a role in supporting the growth of the regional medical tourism market.

Finally, many nations in the region regard medical tourism as a resource for economic development; for instance, the ministries of tourism in Thailand, Malaysia and India have been aggressively and fiercely promoting medical tourism in their countries. In the same vein, private hospital chains and investors perceive medical tourism in Asia Pacific as an attractive business opportunity and invest in infrastructure, equipment, staff and services.

The market is not without its challenges. Chief among them are political stability. Political stability is a requisite to draw any international tourists, irrespective of whether they are travelling for leisure or medical treatment. For instance, political unrest in Thailand and in some Malaysian provinces had an impact, albeit temporary, on medical tourism in these countries. 

But staff shortages also play a role. The volume of adequately trained clinical staff (doctors and nurses) can hardly keep up with the growing numbers of medical tourists and the level and quality of care they expect. Hospitals hire physicians abroad or collaborate with western hospitals to deal with the shortage. At the same time, they review their operational processes and invest in equipment and solutions that impact the productivity of the hospital.

Significant too is competitiveness and cost pressure. The increasing number of hospitals and investors offering global healthcare services creates in competition between countries, often resulting in price wars that can potentially dilute the quality of healthcare provided.

The medical tourism market in ASEAN is in the midst of a boom, and this is impacting the medtech market, among others. For stakeholders that can mitigate these and other operational challenges, the opportunity is abundant. Much of their success, however, will depend on how governments and the private sector can work together to create a conducive medical tourism ecosystem.

This article first appeared on BRINK Asia

Posted on: 08/11/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.